Trump signs order to reduce regulatory barriers to domestic pharmaceutical manufacturing -White House statement
- Trump order directs the U.S. FDA to reduce the amount of time it takes to approve domestic pharmaceutical manufacturing plants
- directs the FDA to improve enforcement of active pharmaceutical ingredient source reporting by foreign drug producers and consider publicly displaying a list of facilities that do not comply
Trump says he’ll have an announcement next week related to cost of medicines
more to come
This article was written by Eamonn Sheridan at www.forexlive.com.
